Apple is testing how consumers respond to conversational medical technology through a new study built around an experimental AI-powered health chat application. The initiative, launched on Sunday in Las Vegas with OpenEvidence, points to a more deliberate push by Apple into the fast-growing intersection of artificial intelligence and personal health tools.
The study was presented during the HLTH conference, a major gathering for health technology companies, investors and medical leaders. Sumbul Desai, Apple’s vice president of health and fitness, said the project is designed to examine how people interact with health-focused chatbots, including what builds trust, how users understand answers and how the quality of those answers can be assessed. She linked the initiative to Apple’s emphasis on scientific rigor and described OpenEvidence as a clinically grounded partner.
OpenEvidence, led by chief executive Daniel Nadler, has positioned itself as a tool trusted by physicians, while Apple has long built its health strategy around consumer devices and software. Nadler framed the collaboration as a combination of complementary strengths: a clinical information product used by doctors and a consumer technology brand with broad reach among people managing health data on everyday devices. No commercial launch details, timeline or broader rollout plans were disclosed during the announcement.
The partnership arrives as technology companies, medical software firms and health systems test the boundaries of digital health assistants. Chat-based systems can make medical information easier to access, but they also raise sensitive questions about accuracy, comprehension and user confidence. By focusing on trust and response quality rather than simply releasing a consumer-facing feature, Apple and OpenEvidence are placing the study in an area where regulatory expectations, clinical evidence and user experience increasingly overlap.
For Apple, the study may signal how future health features could evolve beyond passive tracking and notifications toward more conversational support. For OpenEvidence, the collaboration provides a route to study how a medically oriented AI product performs outside a physician-only context. The outcome of the research could help clarify whether consumers can safely and effectively engage with health chatbots, and what standards may be needed before such tools become a routine part of personal health management.
